PLX - Protalix BioTherapeutics beats Q2 top and bottom line estimates
2023-08-07 06:54:22 ET
- Protalix BioTherapeutics press release ( NYSE: PLX ): Q2 GAAP EPS of $0.21 beats by $0.25 .
- Revenue of $35.08M (+300.9% Y/Y) beats by $24.86M .
- Cash and cash equivalents were approximately $48.2 million at June 30, 2023.
For further details see:
Protalix BioTherapeutics beats Q2 top and bottom line estimates